Company intelligence / Profile preview

Oceanside Pharmaceuticals

Ownership: Private
Development stage: Commercial

Overview

Oceanside Pharmaceuticals provides a portfolio of prescription ophthalmic and other generic pharmaceuticals for diagnostic, anesthetic, anti-inflammatory, and other therapeutic purposes. It operates primarily as a supplier to clinical practices in optometry and ophthalmology. As part of Valeant/Bausch Health Companies since at least 2009, it has launched authorized generics such as chlordiazepoxide hydrochloride + clidinium bromide ("Librax" AG) among others. No proprietary new molecular entities or novel biologics are reported.

Therapeutic areas: EndocrinologyImmunologyGastroenterologyOphthalmologyInfectious Diseases
Modalities: Small molecule
Industry: Biotech

Drug pipeline

1 asset

betahistine

Commercial

Indications: Vertigo

Beyond the preview

Go deeper on Oceanside Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Oceanside Pharmaceuticals.

Explore the full profile